#1 Clinical Trials Search in Europe

Panobinostat

This article explores the use of panobinostat, a novel drug, in clinical trials for various blood cancers and related conditions. Panobinostat is being studied as a potential treatment for multiple myeloma, acute myeloid leukemia, myelodysplastic syndromes, and other hematologic malignancies. The trials aim to evaluate its safety, efficacy, and optimal dosing regimens when used alone or in combination with other therapies.

Table of Contents

What is Panobinostat?

Panobinostat, also known by its brand name Farydak or research code LBH589, is an investigational drug that belongs to a class of medications called histone deacetylase (HDAC) inhibitors[1]. HDAC inhibitors are a type of drug that can affect how genes are expressed in cells, potentially stopping cancer cells from growing or causing them to die[2].

Panobinostat is considered a pan-HDAC inhibitor, meaning it can inhibit multiple types of HDAC enzymes. This broad action makes it a promising candidate for treating various types of cancer and blood disorders[1].

What Conditions Does Panobinostat Treat?

Panobinostat is being studied for its potential to treat several conditions, including:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells in the bone marrow[3]
  • Acute Myeloid Leukemia (AML): A cancer of the blood and bone marrow[4]
  • Myelodysplastic Syndromes (MDS): A group of disorders where blood cells don’t mature properly in the bone marrow[5]
  • Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma: Types of cancer that affect the lymphatic system[2]
  • Soft Tissue Sarcoma: A rare type of cancer that begins in the tissues that connect, support, and surround other body structures[1]
  • Glioblastoma: An aggressive type of brain cancer[6]
  • Myelofibrosis: A rare type of blood cancer that affects bone marrow function[7]
  • Sickle Cell Disease: An inherited red blood cell disorder[8]

How Does Panobinostat Work?

Panobinostat works by inhibiting histone deacetylase enzymes, which play a crucial role in regulating gene expression. By blocking these enzymes, panobinostat can:

  • Interfere with cancer cell growth and survival[1]
  • Increase the production of hemoglobin F (fetal hemoglobin) in sickle cell disease, which can improve outcomes[8]
  • Potentially enhance the effectiveness of other cancer treatments[4]
  • Reduce inflammation, which is important in many blood disorders[8]

How is Panobinostat Administered?

Panobinostat is typically given as an oral medication in the form of capsules. The dosing schedule can vary depending on the condition being treated and the specific clinical trial protocol. Some common dosing regimens include:

  • 20 mg taken orally three times a week (e.g., Monday, Wednesday, Friday) every week or every other week[9]
  • 10 mg to 40 mg taken three times a week, with the dose adjusted based on how well it’s tolerated[4]
  • In some cases, it may be given in combination with other medications or treatments[2]

It’s important to note that the optimal dosing for panobinostat is still being studied in various clinical trials.

Panobinostat in Clinical Trials

Panobinostat is being evaluated in numerous clinical trials for different conditions. Some notable studies include:

  • A phase II trial for soft tissue sarcoma, exploring its efficacy in patients who have failed previous treatments[1]
  • A study examining its use as maintenance therapy after stem cell transplantation in patients with high-risk AML or MDS[4]
  • A trial investigating its potential in treating sickle cell disease[8]
  • Research on its effectiveness in multiple myeloma patients after autologous stem cell transplantation[3]

Potential Side Effects

As with any medication, panobinostat can cause side effects. Common side effects reported in clinical trials include:

  • Fatigue[1]
  • Gastrointestinal issues (nausea, diarrhea, decreased appetite)[7]
  • Changes in blood cell counts[4]
  • Electrolyte imbalances[7]

The severity and frequency of side effects can vary depending on the dose and individual patient factors. It’s crucial for patients to report any side effects to their healthcare team promptly.

Ongoing Research and Future Directions

Research on panobinostat is ongoing, with scientists exploring its potential in various areas:

  • Combination therapies: Studies are investigating how panobinostat works when combined with other cancer treatments[4]
  • Biomarkers: Researchers are looking for biological markers that might predict which patients will respond best to panobinostat[7]
  • Long-term effects: Clinical trials are assessing the long-term safety and efficacy of panobinostat in different patient populations[9]
  • New indications: Studies are exploring the potential of panobinostat in treating other conditions beyond its current uses[8]

As research progresses, our understanding of panobinostat’s role in treating various diseases continues to evolve. Patients interested in panobinostat should discuss the latest developments and potential treatment options with their healthcare providers.

Aspect Details
Drug Name Panobinostat (also known as LBH589, Farydak)
Drug Class Histone deacetylase inhibitor (HDACi)
Conditions Studied Multiple myeloma, Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS), Sickle cell disease, Glioblastoma
Administration Oral capsules, typically 3 times per week
Dosage Range 10-60 mg, depending on the specific trial and condition
Treatment Duration Varies by trial, ranging from 12 weeks to 1 year or longer
Primary Outcomes Safety, tolerability, maximum tolerated dose, overall response rate, progression-free survival
Secondary Outcomes Overall survival, quality of life, pharmacokinetics, pharmacodynamics, biomarker analysis
Combination Therapies Studied alone and in combination with other treatments (e.g., stem cell transplantation)
Special Populations Adults and children with various hematologic malignancies and related conditions

FAQ

  • What is panobinostat? Panobinostat is a histone deacetylase inhibitor (HDACi) that interferes with gene expression in cells, causing them to stop growing or die. It is being investigated as a potential treatment for various blood cancers and related conditions.
  • What types of cancers is panobinostat being studied for? Panobinostat is being studied in clinical trials for multiple myeloma, acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), sickle cell disease, and other hematologic malignancies.
  • How is panobinostat administered? Panobinostat is typically administered orally in capsule form. The dosing schedule varies depending on the specific trial, but it is often given three times a week on a set schedule (e.g., Monday, Wednesday, Friday).
  • What are some potential side effects of panobinostat? While side effects can vary, some potential adverse events associated with panobinostat include gastrointestinal issues, fatigue, and changes in blood cell counts. The clinical trials are designed to monitor and assess the safety profile of the drug.
  • How long do patients typically receive panobinostat in clinical trials? The duration of panobinostat treatment in clinical trials varies. Some studies administer the drug for a set number of cycles (e.g., 6-8 cycles of 28 days each), while others may continue treatment for up to a year or longer, depending on the patient's response and tolerance.

Ongoing Clinical Trials on Panobinostat

  • Study on Personalized Treatment for Metastatic Colorectal Cancer Using Methotrexate and Drug Combination for Patients with Advanced Disease

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Sweden

  • Study on Reversing HIV Latency Using Pyrimethamine, Lenalidomide, and Panobinostat for People Living with HIV

    Not recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Histone deacetylase inhibitor (HDACi): A class of drugs that block the action of histone deacetylases, enzymes involved in gene expression regulation. HDACi drugs like panobinostat can affect cancer cell growth and survival.
  • Multiple myeloma: A type of blood cancer that affects plasma cells, a type of white blood cell found in bone marrow. It can lead to bone damage, kidney problems, and other complications.
  • Acute myeloid leukemia (AML): A fast-growing cancer of the blood and bone marrow, characterized by the rapid production of abnormal white blood cells that interfere with normal blood cell production.
  • Myelodysplastic syndromes (MDS): A group of disorders caused by poorly formed or dysfunctional blood cells, which can lead to anemia, infections, or easy bleeding and may progress to acute leukemia.
  • Hematopoietic stem cell transplantation (HSCT): A procedure that replaces damaged or diseased bone marrow with healthy stem cells, which can then produce new, healthy blood cells.
  • Graft-versus-host disease (GvHD): A complication that can occur after a stem cell or bone marrow transplant, where the donor's immune cells attack the recipient's tissues.
  • Graft-versus-leukemia (GvL) effect: A beneficial effect where transplanted donor immune cells recognize and attack remaining cancer cells in the recipient's body after a stem cell transplant.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive.
  • Maximum tolerated dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.

References

  1. https://clinicaltrials.gov/study/NCT01136499
  2. https://clinicaltrials.gov/study/NCT01321346
  3. https://clinicaltrials.gov/study/NCT02722941
  4. https://clinicaltrials.gov/study/NCT01451268
  5. https://clinicaltrials.gov/study/NCT00594230
  6. https://clinicaltrials.gov/study/NCT01115036
  7. https://clinicaltrials.gov/study/NCT00931762
  8. https://clinicaltrials.gov/study/NCT01245179
  9. https://clinicaltrials.gov/study/NCT04326764